Fonti scientifiche Pickart L, Vasquez-Soltero JM, Margolina A

Disclosure of interest: Elisabeth Hofstaetter: Medical Lead of Novartis Pharma GmbH, All other authors: nothing to disclose Poster Session I - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P389 - ESOC25-2231 ADDRESSING GENDER DISPARITIES IN CEREBROVASCULAR CLINICAL TRIALS: BARRIERS AND STRATEGIES FOR INCLUSION Virginia Cancelloni 1 , Victoria Rcker 2 , Kirsten Harvey 3 , Kirsten Haas 2 , Peter Heuschmann 2 , Bianca Koehler 1 , Mara Graziani 1 , Roland Veltkamp 3,4 , Valeria Caso 1 1 Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Perugia, Italy, 2 Institute of Clinical Epidemiology and Biometry, University of Wrzburg, Wrzburg, Germany, 3 Department of Brain Sciences, Imperial College London, London, United Kingdom, 4 Department of Neurology, Alfried Krupp Krankenhaus Essen, Essen, Germany Background and Aims: The underrepresentation of women in cerebrovascular randomised control trials (RCTs) remains a pressing issue

Studies in animal models show consistent effects on gut wall integrity, including reduction of intestinal permeability markers associated with leaky gut
Weeks 1-2: 5 units per injection (0.5 mg) Weeks 3-8: 8 units per injection (0.8 mg) Frequency: Once daily, 5 days on, 2 days off Timing: Morning injection Cycle length: 2 months active, 2 months off The ramp-up is intentional
BMJ open
Their experience suggested that the patchy hypopigmentation tended to resolve after 30-40 doses due to the evolution of a uniform skin-lightening effect Depletion of natural hepatic stores of glutathione: Hypothetically, long-term supplementation with any external synthetic compound may signal the body to stop its own production resulting in dependence on synthetic supplements